What’s Next? Five Things To Look Out For In June
Organon Begins Life As Independent Company
In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.
